Transfusion of blood products is a life-saving ... versus-Host disease, a transfusion-related complication ... related acute lung injury (TRALI) is mostly based on.
the expression of the highly homologous RHD and. RHCE genes located on human chromosome 1, which respectively encode the RhD and the RhCE.
Medical Center and Bellevue Hospital Center (New. York, NY, USA), were eligible for the study. The exclusion criteria were a 5-minute Apgar score of 3 or.
However, although leucoreduced units of packed red blood cells contain fewer than 5Ã106 white blood cells, it should be noted that neutrophils, which undergo.
the basis of a history of a previously failed mobilisation attempt or the presence of ... blood cell count recovery, measuring the circulating. CD34+ cells as soon as ...
Although the most common sources of anaemia among patients undergoing orthopaedic surgery are related to iron deficiency and chronic diseases, given their.
Importance of information provision in the acceptance of blood donation .... full questionnaire can be found in Online S
any dose of epoetin alfa or darbepoetin, compared with placebo, significantly reduced the odds of ARBC exposure (OR =0.73, 95% CI 0.64-0.84, I² =54.7%), and.
Infectious agents, Leptospira spp. and Bartonella spp., in blood donors from Cajamarca .... borgpetersenii, L. weilii, L. noguchii, L. santarosai,. L. meyeri and L.
oxygen carriers as alternatives to allogeneic blood transfusion. 1. ...... synthetic antifibrinolytic agents in orthopaedic surgery is an "off-label" indication, and more ...
production, pH, pCO2, ATP, hypotonic shock response reactivity, CD62P, PAC-1, platelet endothelial cell adhesion molecule-1 or CD42b. The release of ...
Oct 8, 2013 - 41) Santagostino E, Mancuso ME, Rocino A, et al. ... 46) Mancuso ME, Mannucci PM, Rocino A, et al. Source ..... Anna Brigida Aru (Cagliari).
that PolyHeme administration may improve survival in extreme circumstances220, a recent clinical trial demonstrated that PolyHeme use did not provide any.
transmitted feco-orally by contaminated water, causing .... In the industrial plants, each donated plasma ... RT-PCR kit 1.0, Altona Diagnostics GmbH, Hamburg,.
literature data, we discuss the role of ABO blood types as prognostic biomarkers in ... ABO blood group antigens are defined by carbohydrate moieties on the ...
(OR) and 95% confidence intervals (95% CI). For categorical outcomes, multinomial regression was performed. For ordinal
references. 1) Kniffin WD, Baron JA, Barrett J, et al. ..... natural anticoagulant AT, PC, or PS is difficult to determine ...... oF portal vEin thromboSiS and budd-chiari.
Giovanni Lombardi1, Giuseppe Banfi1,2, Giuseppe Lippi3, Fabian Sanchis-Gomar4. 1I.R.C.C.S. Galeazzi .... Correspondence: Giovanni Lombardi. Laboratory of ...
following treatment with rituximab and bendamustine in combination in a heavily pre-treated patient with CAD not responding to previous chemotherapies8.
Attitudes and behaviours of Greeks concerning blood donation: ... 88.0% of the individuals believed that donating blood was an "offer". Reasons ..... (answer; "I don't care"), personal gain (answer; "I donate for personal gain") and offer (answer; "o
Recent evidence shows that an enhanced cell-free haemoglobin (fHb) concentration ... associated with haemolytic anaemia include immune and autoimmune ...
Introduction. Rare Diseases (RDs) are defined in Europe as those that affect fewer than 5 in 10,000 people. They have specific characteristics as a low ...
1Transfusion Service, Haemophilia Centre and Haematology, 2Laboratory Analysis, Castelfranco Veneto Hospital,. Castelfra
and synthesis of regenerative proteins3-7. ... PRP injections (one treatment every 7 days) and each of .... training programme based on a physiatrist's physical.
carried out for the treatment of hyperleucocytosis at the Haematology and ..... leukostasis and leukapheresis: practice management. Blood ... Emergency.
Original Article Therapeutic leukapheresis: 9-year experience in a University Hospital Ingrid M. Parra Salinas1, Victoria P. González Rodriguez1, José A. García-Erce2 Haematology Department, Miguel Servet University Hospital, Zaragoza; 2Haematology Department, San Jorge Hospital, Huesca, Spain
1
TI S
er v
iz i
Sr l
Background. Hyperleucocytosis is associated with higher morbidity and mortality related to possible development of leucostasis, tumour lysis syndrome and/or disseminated intravascular coagulation. There is insufficient evidence of the need for leukocytapheresis during early treatment of hyperleucocytosis, and its efficiency remains controversial, although leucoreduction is a measure that can prevent adverse events and death. The aim of this study was to analyse the safety and effectiveness of therapeutic leukocytapheresis and its influence on early mortality in our case series, adjusted to independent mortality risk factors described in the literature. Materials and methods. This was a retrospective review (June 2003-June 2012) of procedures carried out for the treatment of hyperleucocytosis at the Haematology and Haemotherapy Service of Miguel Servet University Hospital. The patients' data and technical information were prospectively registered for each leukocytapheresis session. Results. Thirteen patients underwent a total of 27 leukocytapheresis procedures. After an average of two sessions, a statistically significant drop in the initial leucocyte counts was observed (p
